



V. Koblížek, V. Zindr, J. Kociánová, S. Holub, A. Hrazdířová  
Hradec Králové, Karlovy Vary, Ostrava, Teplice, Brno

## Praktický přínos sledování CAT




### Chytré postupy bývají „jednoduché“

- Checking chest pain, bleeding out, blood loss. **A&E or 999** Emergencies only
- Hearted? Covered? Confused? Head foggy? **Call 111** out of hours
- Worring? Not well? Not back to work? **GP Surgery**
- Diagnosing? Dizziness? Double vision? Headache? **Pharmacy**

SG NHS 2016

## CAT - COPD ASSESSMENT TEST



2009 2011

obtain, from the patient, reliable and valid information on the impact of COPD on their health status. This would include information on



16 May 2009 9:16 AM  
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

### Development and first validation of the COPD Assessment Test

P.W. Jones<sup>a</sup>, G. Harding<sup>a</sup>, P. Berry<sup>a</sup>, I. Wiklund<sup>a</sup>, W.-H. Chen<sup>a</sup> and R. Kline Leidy<sup>a</sup>

Country	Subjects	CAT score
Belgium	71	21.5 ± 9.9
France	294	18.2 ± 8.8
Germany	431	18.2 ± 8.1
The Netherlands	100	16.0 ± 7.4
Spain	369	16.4 ± 8.9
USA	279	17.8 ± 7.5

FIGURE 2. Cumulative frequency distribution of COPD Assessment Test (CAT) scores in 1,503 patients with stable chronic obstructive pulmonary disease. COPD, 10% of patients used 0% of the scaling range, 10% of patients had a score of 10% and 10% had a score >30.

16 May 2009 9:16 AM

### AE - ↑ o 5 (CAT) resp. ↑ o 12 (SGRQ)




FIGURE 3. Pearson correlation between scores in the chronic obstructive pulmonary disease (COPD)-specific version of the St George's Respiratory Questionnaire (SGRQ-C) and COPD Assessment Test (CAT) in 239 stable patients from the USA. (n=239, p<0.001).

FIGURE 4. Box and whisker plot of COPD Assessment Test (CAT) scores of 239 stable patients and 47 patients measured on the day of presentation with an acute exacerbation. COPD, chronic obstructive pulmonary disease. Boxes represent median and interquartile ranges, whiskers represent 10% and 90% limits. ■ Individual patients who lie outside the 10% and 90% limits (n=350) (excluded from analysis).

## AE – rozdílný v CAT u AE a non-AE pts

2012

**Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations.**

**Abstract**  
**RATIONALE:** The Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is an eight-item questionnaire designed to assess and quantify the impact of COPD symptoms on health status. COPD exacerbations impair quality of life and are characterized by worsening respiratory symptoms from the stable state. We hypothesized that CAT scores at exacerbation relate to exacerbation severity as measured by exacerbation duration, lung function impairment, and systemic inflammation.  
**OBJECTIVES:** To evaluate the usefulness of the CAT to assess exacerbation severity.  
**METHODS:** One hundred sixty-one patients enrolled in the London COPD cohort completed the CAT at baseline (stable state), exacerbation, and during recovery between April 2010 and June 2010.  
**MEASUREMENTS AND MAIN RESULTS:** Frequent exacerbation (≥ 4 exacerbations per year) was associated with higher baseline CAT scores (10.4 vs 8.6,  $P = 0.002$ ). In 192 exacerbations, CAT scores rose from an average baseline value of 10.4 ± 6.8 to 24.1 ± 7.3 ( $P < 0.001$ ) at exacerbation. Change in CAT score from baseline to exacerbation onset was significantly but weakly related to change in C-reactive protein ( $\beta = 0.26$ ,  $P = 0.008$ ) but not to change in feNO ( $\beta = 0.09$ ,  $P = 0.381$ ) from baseline to exacerbation. At exacerbation, rises in CAT scores were significantly associated with falls in FEV1 ( $\beta = -0.26$ ,  $P = 0.032$ ). Median recovery time as judged by symptom diary cards was significantly related to the time taken for the CAT score to return to baseline ( $\beta = 0.42$ ,  $P = 0.02$ ).  
**CONCLUSIONS:** The CAT provides a reliable score of exacerbation severity. Baseline CAT scores are elevated in frequent exacerbators. CAT scores increase at exacerbation and reflect severity as determined by lung function and exacerbation duration.

## RHB - ↓ o 2-3 (CAT) resp. ↓ o 4 (SGRO)

2011

**Thorax**

Study	Effect Size	95% CI	p-value
CAT (n=107)	23.5(4.7)	17.5(4.7) - 29.5(4.8)	<0.001
SGRO (n=107)	7.3(4.2)	1.1(4.2) - 13.5(4.3)	<0.001
SGRO (n=107)	6.7(4.2)	2.5(4.2) - 10.9(4.3)	<0.001
COPD score (n=107)	14.5(4.1)	10.3(4.1) - 18.7(4.2)	<0.001
SGRO vs CAT	16.2(4.7)	11.5(4.7) - 20.9(4.8)	<0.001
SGRO vs COPD score	2.8(4.1)	-1.3(4.1) - 6.9(4.2)	0.8
SGRO vs CAT	2.8(4.1)	-1.3(4.1) - 6.9(4.2)	0.8
SGRO vs COPD score	48.7(4.1)	44.5(4.1) - 52.9(4.2)	<0.001
SGRO vs CAT	23.5(4.7)	17.5(4.7) - 29.5(4.8)	<0.001

MCID CAT možná ± 6

**Chronic obstructive pulmonary disease**  
**The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study**

James Wright<sup>1</sup>, Lawrence King<sup>2</sup>, Jane Walker<sup>3</sup>, James Walker<sup>4</sup>, Amy O'Keefe<sup>5</sup>, Victoria M Goff<sup>6</sup>, Christine Fagan<sup>7</sup>, Rachel Ormerod<sup>8</sup>, Cassandra Lewis<sup>9</sup>, Malcolm Holmes<sup>10</sup>, Paul W Jones<sup>11</sup>, William G Sturt<sup>12</sup>, Nicholas A Hopwood<sup>13</sup>

## Efekt RHB na CAT trvá minimálně 6M

2012

**The COPD Assessment Test (CAT): short- and medium-term response to pulmonary rehabilitation.**

**Abstract**  
**BACKGROUND:** The COPD Assessment Test (CAT) is a recently introduced instrument to assess health-related quality of life in COPD. We aimed to evaluate the longitudinal change in CAT following Pulmonary Rehabilitation (PR), and test the relationship between CAT and CRQ-Self Report (SR) over time. We hypothesized that the CAT would show similar responsiveness to PR as the CRQ-SR both in the short and medium-term.  
**METHODS:** 118 COPD patients completed an eight-week outpatient multidisciplinary PR programme. CAT, CRQ-SR and the incremental shuttle walk (ISW) were measured prior to starting PR (T1), completion of PR (T2) and 6 months after completion of PR (T3).  
**RESULTS:** There was a significant improvement in CAT, CRQ-SR and ISW immediately following PR ( $p < 0.001$ ). Although there was decline between T2 and T3, CAT, CRQ-SR and ISW remained significantly better at T3 compared with T1 (ANOVA  $p < 0.001$ ). Both between T1-T2 and between T2-T3, change in CAT correlated significantly with change in CRQ (both  $r > 0.44$  and  $p < 0.001$ ). The slope of the relationship between CAT change and CRQ-SR change at T1-T2 and T2-T3 was not significantly different (ANOVA, intercept  $p = 0.79$ , interaction effect  $p = 0.95$ ).  
**CONCLUSIONS:** In COPD, the CAT score is sensitive to response to PR and remains elevated at 6 months. There is no significant difference in the short and medium term changes in the CAT and CRQ-SR following PR. We propose that for most clinical indications for assessing health-related quality of life in COPD, the CAT is a robust and practical alternative to longer-established instruments such as the CRQ-SR.

## CAT a KOMORBIDITY (WE)

2011

**Properties of the COPD assessment test in a cross-sectional European study**

P. W. Jones<sup>1</sup>, S. Braccioni<sup>2</sup>, R. B. Dal Negro<sup>3</sup>, M. Fagan<sup>4</sup>, P. Kanner<sup>5</sup>, M. L. Levy<sup>6</sup>, T. Pomeroy<sup>7</sup>, J. J. Sellar Caballero<sup>8</sup>, Y. van den Meulen<sup>9</sup>, L. Adams<sup>10</sup> and R. Bialek<sup>11</sup>

**ABSTRACT:** A short, easy-to-use health questionnaire is needed in the multinational assessment of chronic obstructive pulmonary disease (COPD) in routine practice. The performance of the eight-item COPD assessment test (CAT) was analysed in 1,817 patients from primary care in seven European countries. The CAT has a scoring range of 0-40 (high scores representing poor health status). Mean CAT scores indicated significant health status impairment that was related to severity of airflow obstruction, but within each Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (0-IV) there was a wide range of scores (0: 10.2 (s.d. 6.8); I: 16.3 (7.6); II: 19.3 (8.6); III: 23.2 (8.1); IV: 30.8 (6.8);  $p < 0.0001$ ). In reverse (I-IV), 8.5% versus those suffering an exacerbation (21.3 (4.4);  $p < 0.0001$ ) and in patients with mild (7.4 (4.1)) or severe (17.8 (4.8)) versus those with no (9.7 (4.6)) comorbidity ( $p < 0.0001$ ) for both. The CAT distinguished between classes of their measurement measures and was strongly correlated with the St George's Respiratory Questionnaire ( $r = 0.84$ ,  $p < 0.0001$ ). The CAT is a short, easy-to-use questionnaire that distinguishes between patients of different degrees of COPD severity and appears to behave the same way across countries.

## CAT a komorbidity (CEE)

2016

**CONCLUSIONS:** In COPD, the CAT score is sensitive to response to PR and remains elevated at 6 months. There is no significant difference in the short and medium term changes in the CAT and CRQ-SR following PR. We propose that for most clinical indications for assessing health-related quality of life in COPD, the CAT is a robust and practical alternative to longer-established instruments such as the CRQ-SR.

## CAT a mMRC (n 1817)

2013

**Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification**

Paul W. Jones<sup>1</sup>, Lukasz Adamski<sup>2</sup>, Gilbert Houbart<sup>3</sup> and Herbert Bussel<sup>4</sup>

**CONCLUSIONS:** In COPD, the CAT score is sensitive to response to PR and remains elevated at 6 months. There is no significant difference in the short and medium term changes in the CAT and CRQ-SR following PR. We propose that for most clinical indications for assessing health-related quality of life in COPD, the CAT is a robust and practical alternative to longer-established instruments such as the CRQ-SR.

## CAT a mMRC (n 18.577)

Smid et al 2017

## CAT u „zdravých pracujících“

2013

Group	Mean	Median	SD	Max	Floor effect
All subjects	6.4	6.0	4.0	26.0	7.4%
Non-COPD	6.3	6.0	4.0	24.0	7.3%
COPD defined by fixed ratio	7.5	6.4	7.8	31.5	5.9%
Non-COPD defined by LIL	6.3	5.3	5.6	31.5	8.6%
COPD defined by LIL	8.4	6.7	7.5	34.0	13.4%
Healthy non-smoking (unemployed)	5.0	4.9	4.2	15.5	5.07%
Healthy smoking subject*	6.8	5.8	5.1	31.1	7.5%
COPDGOLD-stage1	8.1	5.7	5.2	31.5	5.9%
COPDGOLD-stage2	7.5	6.4	6.1	26.8	8.9%

## CAT u „zdravých“

2014

The overall mean CAT 6  
CAT higher among females 6.43  
and subjects over 80 years 7.58

CAT 16 was the 95th percentile

Current smoking, subject-reported physician-diagnosed asthma, and musculoskeletal disease were significantly associated with  $\geq 16$

## Co dělá věk s CAT ?

2016

Determinants of chronic obstructive pulmonary disease differ from those in younger

CAT roste s věkem u osob s mírnější obstrukcí

Table 3. CAT self-search for reasons of GOLD diagnosis (definition of GOLD AD vs AE)

Code	Reason	Specific	Age
1.0	1	1	1
1.1	1	1	1
1.2	1	1	1
1.3	1	1	1
1.4	1	1	1
1.5	1	1	1
1.6	1	1	1
1.7	1	1	1
1.8	1	1	1
1.9	1	1	1
1.10	1	1	1
1.11	1	1	1
1.12	1	1	1
1.13	1	1	1
1.14	1	1	1
1.15	1	1	1
1.16	1	1	1
1.17	1	1	1
1.18	1	1	1
1.19	1	1	1
1.20	1	1	1
1.21	1	1	1
1.22	1	1	1
1.23	1	1	1
1.24	1	1	1
1.25	1	1	1
1.26	1	1	1
1.27	1	1	1
1.28	1	1	1
1.29	1	1	1
1.30	1	1	1
1.31	1	1	1
1.32	1	1	1
1.33	1	1	1
1.34	1	1	1
1.35	1	1	1
1.36	1	1	1
1.37	1	1	1
1.38	1	1	1
1.39	1	1	1
1.40	1	1	1
1.41	1	1	1
1.42	1	1	1
1.43	1	1	1
1.44	1	1	1
1.45	1	1	1
1.46	1	1	1
1.47	1	1	1
1.48	1	1	1
1.49	1	1	1
1.50	1	1	1

## CAT a fenotypy

2016

Figure 3. Occurrence of COPD phenotypes with the growth of CAT

CAT 1 - cough  
CAT 2 - phlegm in chest  
CAT 3 - lightness on chest  
CAT 4 - waking up at night  
CAT 5 - activities at home  
CAT 6 - compliant to leave home  
CAT 7 - sleep soundly  
CAT 8 - energy  
CAT 9 - total

CAT pomáhá s fenotypy

Table 3. CAT self-search for reasons of GOLD diagnosis (definition of GOLD AD vs AE)

Code	Reason	Specific	Age
1.0	1	1	1
1.1	1	1	1
1.2	1	1	1
1.3	1	1	1
1.4	1	1	1
1.5	1	1	1
1.6	1	1	1
1.7	1	1	1
1.8	1	1	1
1.9	1	1	1
1.10	1	1	1
1.11	1	1	1
1.12	1	1	1
1.13	1	1	1
1.14	1	1	1
1.15	1	1	1
1.16	1	1	1
1.17	1	1	1
1.18	1	1	1
1.19	1	1	1
1.20	1	1	1
1.21	1	1	1
1.22	1	1	1
1.23	1	1	1
1.24	1	1	1
1.25	1	1	1
1.26	1	1	1
1.27	1	1	1
1.28	1	1	1
1.29	1	1	1
1.30	1	1	1
1.31	1	1	1
1.32	1	1	1
1.33	1	1	1
1.34	1	1	1
1.35	1	1	1
1.36	1	1	1
1.37	1	1	1
1.38	1	1	1
1.39	1	1	1
1.40	1	1	1
1.41	1	1	1
1.42	1	1	1
1.43	1	1	1
1.44	1	1	1
1.45	1	1	1
1.46	1	1	1
1.47	1	1	1
1.48	1	1	1
1.49	1	1	1
1.50	1	1	1

## Co když s CAT pomáháme ?

2017

Výsledek CAT může ovlivnit zdravotník (mMRC nikotiv)

		Lean patient	Patient calibration	p <sup>1</sup>		
		Median (IQR, percent)	Median (IQR, percent)			
Calibration	N = 38	45.0 (4.30-50.0)	45.0 (8.0)	10.0 (5.0-27.0)	<0.001	
Median Calibration	N = 200	45.0 (4.30-50.0)	45.0 (4.3)	10.0 (4.3-24.0)	<0.001	
Calibration Very	N = 99	14.0 (4.30-20.0)	15.0 (7.0)	7.0 (4.3-22.0)	8.9 (6.0)	<0.001
Lean	N = 82	15.0 (4.30-20.0)	12.0 (5.0)	10.0 (4.3-20.0)	14.0 (8.0)	<0.001
Discrete	N = 77	45.0 (4.30-50.0)	45.0 (7.0)	14.0 (4.3-20.0)	15.0 (7.0)	0.002
Topical	N = 43	15.0 (4.3-20.0)	15.0 (7.0)	15.0 (4.3-20.0)	14.0 (8.0)	<0.001

## Závěr

- CAT určuje dopad na nemocné (podobně jako SGRQ total)



## Závěr

- CAT určuje dopad na nemocné (podobně jako SGRQ total)
- CAT je lehce ovlivněn pohlavím, věkem a komorbiditami



## Závěr

- CAT určuje dopad na nemocné (podobně jako SGRQ total)
- CAT je lehce ovlivněn pohlavím, věkem a komorbiditami
- CAT pomáhá identifikovat zlepšení po RHB či zhoršení po AE



## Závěr

- CAT určuje dopad na nemocné (podobně jako SGRQ total)
- CAT je lehce ovlivněn pohlavím, věkem a komorbiditami
- CAT pomáhá identifikovat zlepšení po RHB či zhoršení po AE
- CAT je zásadním nástrojem pro klasifikaci GOLD



## Závěr

- CAT určuje dopad na nemocné (podobně jako SGRQ total)
- CAT je lehce ovlivněn pohlavím, věkem a komorbiditami
- CAT pomáhá identifikovat zlepšení po RHB či zhoršení po AE
- CAT je zásadním nástrojem pro klasifikaci GOLD
- CAT může nasměrovat při hledání fenotypu



## Implementace ?



„CAT nepoužívám, nenahradí přímý kontakt s pacientem...“



„CAT používáme, pomůže zkvalitnit naši práci a navíc využije čas v čekárně...“



„CAT je snadné používat, jen musí mít pacienti brýle...“



„CAT je základ monitorace pacientů s CHOPN...“